Modalis Therapeutics Corporation announced it will regain full development and commercial rights to MDL-201 and MDL-202 from Astellas Pharma Inc. It also reveals that target indications for the products are Duchene Muscular Dystrophy (DMD) and Myotonic Dystrophy type 1 (DM1), respectively. Modalis is also announcing a sharpened strategic focus, to prioritize its investments in the most promising programs: MDL-101, the lead program in its pipeline which has completed preIND and is moving forward to the clinic for LAMA2-CMD, and MDL-202 for DM1. This matter shall have a minor impact on cost compared with that of the whole R&D for the fiscal year ending December 31, 2023, and the following years.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
70 JPY | -1.41% | -10.26% | -43.55% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,527 JPY | +0.39% | -1.13% | 17.34B | ||
70 JPY | -1.41% | -10.26% | 15.32M | ||
1st Jan change | Capi. | |
---|---|---|
-43.55% | 15.32M | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- 4883 Stock
- News Modalis Therapeutics Corporation
- Modalis Therapeutics Corporation to Regain Full Rights to MDL-201 and MDL-202 from Astellas Pharma Inc